SCHEMBL6771032

SCHEMBL6771032

CCNC(=O)C1(CCCCN2CCN(c3nc4ccccc4n3C)CC2)c2ccccc2-c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRM2 P08172 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
DRD1 P21728 1/20 0.42
TBXA2R P21731 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRM1 P35372 1/20 0.42
DRD3 P35462 1/20 0.42
MTTP P55157 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
MTR Q99707 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777257 0.93 ALDH1A1 (0.45) ALDH1A1HPGDCHRM2ADRA2AADORA3
SCHEMBL6771866 0.90 ALDH1A1 (0.58) ALDH1A1HPGDSMN1; SMN2DRD3
SCHEMBL6769807 0.90 MTTP (0.54) CHRM2ADRA2AADORA3CHRM1DRD1
SCHEMBL6766930 0.88 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2MEN1KMT2ACHRM2
SCHEMBL6772677 0.88 MTTP (0.47) ALDH1A1SMN1; SMN2KMT2ACHRM2ADRA2A
SCHEMBL7594407 0.88 ALDH1A1 (0.45) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL6771329 0.87 ALDH1A1 (0.49) ALDH1A1SLC6A2LMNA
SCHEMBL6769795 0.87 MTTP (0.51) CHRM2ADRA2AADORA3CHRM1DRD1
SCHEMBL6770356 0.84 MTTP (0.50) MEN1KMT2ACHRM2ADRA2AADORA3
SCHEMBL6766926 0.84 HTR1A (0.55) ALDH1A1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A ALDH1A1 715/4885HPGD 1438/4885SMN1; SMN2 4276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.